Genomic testing company Personalis reported a net loss per share of USD 0.67 in Q4 2022, missing analysts’ expectations by 4%. The firm’s net losses for the quarter and full year widened by 54% YoY and 74% YoY, respectively, as Personalis amid a decline in revenue and higher operating expenses.
The completion of all its outstanding task orders from the US Department of Veterans Affairs Million Veterans Program (VA MVP) led to a 19% YoY decline in total revenue in Q4 2022 to USD 16.7 million and also affected revenue for the full year, which slipped 24% YoY to USD 65 million.
The gross margin for Q4 2022 also declined significantly to 14% from 39% due to a decline in revenue despite a shift in revenue mix to high-margin customers. Operating expenses increased on the back of higher R&D costs (up 14% YoY), and selling, general, and administrative expenses (up 30% YoY).
During Q4 2022, the company announced a continuing partnership with Moderna to provide genomic testing for the latter's investigational personalized cancer vaccine's upcoming clinical studies and initiated a research collaboration with University Medical Center Hamburg-Eppendorf to use its' NeXT Personal to track tumor response to immunotherapy (IO) in melanoma patients.
In terms of its 2023 guidance, Personalis expects revenue in the range of USD 68–72 million, implying an increase of 5%–11%. The firm projects a net loss of USD 103 million, down from USD 113 million in 2022 due to savings from layoffs which is partially offset by investments in clinical evidence generation and non-cash depreciation expense for the new facility. It expects cash usage of USD 75 million, down from USD 119 million in 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.